The biological treatment of renal-cell carcinoma and melanoma
Authors:
- Tim G EisenTETim G Eisen
- 1 February 2002
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 3 (2) , 89-96
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- New approaches to the systemic treatment of melanomaCancer Treatment Reviews, 1999
- Regimens With or Without Interferon-α as Treatment for Metastatic Melanoma and Renal Cell Carcinoma: An Overview of Randomized TrialsJournal of Immunotherapy, 1999
- CELLULAR AND HUMORAL IMMUNE RESPONSES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AFTER VACCINATION WITH ANTIGEN PULSED DENDRITIC CELLSJournal of Urology, 1999
- Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guèrin: Five-year results of a prospective randomized studyCancer, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancerEuropean Journal of Cancer, 1993
- Interleukin-6 and renal cell cancer: Production, regulation, and growth effectsCancer Immunology, Immunotherapy, 1992
- Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice.Journal of Clinical Investigation, 1991